Group 1 - The Artemisinin concept index rose by 0.57%, ranking 6th among concept sectors, with six stocks increasing in value, including Delong Huineng, Haizheng Pharmaceutical, and China Resources Double Crane, which rose by 4.38%, 2.49%, and 0.75% respectively [1] - The stocks with the largest declines included Baihua Pharmaceutical, Rundu Co., and Fosun Pharmaceutical, which fell by 2.20%, 0.50%, and 0.15% respectively [1] Group 2 - The main capital flow analysis indicates that the Artemisinin concept sector experienced a net outflow of 73 million yuan, with three stocks receiving net inflows, led by Haizheng Pharmaceutical with a net inflow of 2.9933 million yuan [2] - Other stocks with notable net inflows include Fosun Pharmaceutical and Kunming Pharmaceutical Group, with net inflows of 1.7788 million yuan and 1.4040 million yuan respectively [2] Group 3 - In terms of capital inflow ratios, Kunming Pharmaceutical Group, Haizheng Pharmaceutical, and Fosun Pharmaceutical had the highest net inflow rates at 3.59%, 1.88%, and 0.82% respectively [3] - The capital flow data for the Artemisinin concept shows that Haizheng Pharmaceutical had a daily increase of 2.49% with a turnover rate of 1.25% and a net inflow of 2.9933 million yuan [3] - Conversely, stocks like Rundu Co. and Zhejiang Medicine experienced negative net inflows of -2.35 million yuan and -3.5082 million yuan respectively, with net inflow rates of -4.49% and -5.28% [4]

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [2] Core Views - The pharmaceutical and biotechnology industry index experienced a decline of 4.40%, ranking 23rd among 31 primary industries, underperforming the CSI 300 index which fell by 2.19% [6][18] - The valuation of the pharmaceutical and biotechnology industry as of November 28, 2025, is a PE (TTM overall method, excluding negative values) of 29.46x, down from 30.89x in the previous period, indicating a downward trend and below the average [22] - The report highlights potential beneficiaries from the upcoming ASH data, particularly in blood diseases and companies with solid grassroots channels, as well as those with differentiated advantages in oncology, autoimmune, and rare disease products [10] Summary by Sections Industry Review - The pharmaceutical and biotechnology industry index fell by 4.40%, with chemical preparations and medical devices showing declines of 2.86% and 2.95% respectively, while offline pharmacies and vaccines saw larger declines of 8.22% and 6.42% [6][18] - The PE ratio for the pharmaceutical and biotechnology industry is 29.46x, with the highest valuations in the vaccine (47.56x), hospital (41.17x), and medical device (36.77x) sectors, while pharmaceutical circulation has the lowest at 14.58x [22] Important Industry News - The National Administration of Traditional Chinese Medicine and the National Healthcare Security Administration released a directory for traditional Chinese medicine diseases suitable for disease-based payment [26][27] - AstraZeneca's drug "Durvalumab" received FDA approval for a new indication in perioperative treatment of gastric cancer [32] - Otsuka Pharmaceutical's new drug for IgA nephropathy, "Sibeprenlimab," has been approved by the FDA [38] - Bayer's first-in-class lung cancer drug "Sevabertinib" has been approved by the FDA for specific patient populations [40] Investment Recommendations - Focus on innovative pharmaceutical companies that may benefit from the medical insurance or commercial insurance directories, blood cancer targets with imminent ASH data releases, and biotech and CXO leaders with solid technology platforms and international collaboration expectations [10]

Core Viewpoint - Zhejiang Medicine is actively expanding its financing channels and improving its industrial chain layout through the planned spin-off of its subsidiary, New Code Biology, for a listing in Hong Kong, alongside significant investments in its main business [1][2]. Group 1: Spin-off and Investment Plans - Zhejiang Medicine announced plans to spin off its subsidiary, New Code Biology, for a Hong Kong listing to optimize resource allocation and broaden financing channels, aiming to enhance its biopharmaceutical business and overall profitability [2][3]. - New Code Biology, a leader in the vitamin sector, focuses on the research and production of biopharmaceuticals and has recently acquired strategic assets to strengthen its R&D pipeline [2]. - The spin-off will not affect Zhejiang Medicine's control over New Code Biology or its other business segments, maintaining operational stability [2][3]. Group 2: Financial Performance - For the first three quarters of 2025, Zhejiang Medicine reported a revenue decline of 5.87% to 66.95 billion, but achieved a net profit of 9.33 billion, reflecting a year-on-year growth of 9.83% [4][5]. - The company’s operating cash flow reached 14.89 billion, marking a significant increase of 115.11% year-on-year, indicating strong profitability and risk resilience [4][5]. Group 3: Strategic Projects - Zhejiang Medicine is investing 16.85 billion in the Changbei Biological Project, which aims to enhance its vitamin intermediate production and develop high-value-added products, with expected annual sales of 9 billion and a gross profit of 2.86 billion [4]. - The project is planned in two phases, with the first phase focusing on vitamin intermediates and expected to complete by November 2027 [4]. Group 4: Shareholder Engagement - To enhance team engagement and operational vitality, Zhejiang Medicine is implementing a share buyback and stock incentive plan, having completed a buyback of 2 billion and initiated a new stock incentive plan for 875 employees [5].

Group 1 - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [1] - Anhui Construction won two major EPC projects with a total bid price of 2.603 billion yuan [2] - Tianrun Dairy's wholly-owned subsidiary received a government subsidy of 7.9094 million yuan, representing 18.12% of the company's audited net profit for 2024 [2] Group 2 - Yunnan Gold's subsidiary obtained a mining license for the Xinxiao County Tanxi Tungsten Mine, with a production capacity of 990,000 tons per year [5][22] - Yanzhou Coal Energy plans to acquire 100% equity of a high-end support company for 345 million yuan [6] - Heng Rui Pharmaceutical received approval for multiple drug clinical trials, including Sulfate Amexitin tablets [8] Group 3 - Huazhi Jie plans to invest 157 million yuan to establish five wholly-owned subsidiaries to expand its global strategy [1] - Junting Hotel's controlling shareholder is planning a change of control, leading to a continued suspension of trading [4] - Funi Technology's shareholder plans to reduce its stake by up to 1.68% [10] Group 4 - Midea Group's subsidiary received a government subsidy of 6 million yuan, which is 58.27% of the company's latest audited net profit [1] - Hunan Gold's subsidiary obtained a mining license for tungsten, iron, and silver, with a production scale of 990,000 tons per year [5][22] - Xin Hua Pharmaceutical received approval for the listing application of Acetate Prednisone raw material [24][25] Group 5 - Zhejiang Pharmaceutical plans to spin off its subsidiary for a listing on the Hong Kong Stock Exchange [28] - Kesheng Technology plans to invest 61.2 million yuan to acquire 51% of Shenzhen Guanding [30] - Tian Shan Aluminum's 1.4 million tons electrolytic aluminum green low-carbon energy efficiency improvement project has commenced production [38]

Core Viewpoint - Zhejiang Medicine (600216) plans to spin off its subsidiary Zhejiang Xima Bio-Pharmaceutical Co., Ltd. for a listing on the Hong Kong Stock Exchange, with the board having approved the preparatory work [1] Group 1: Spin-off Details - The spin-off is currently in the preliminary planning stage, and specific plans have not yet been formed, indicating uncertainty [1] - The spin-off will not result in Zhejiang Medicine losing control over Xima Bio, nor will it adversely affect the operational development of other business segments or the overall profitability of the company [1] Group 2: Impact on Company Structure - The spin-off will not harm the independent listing status of Zhejiang Medicine [1]

Group 1 - Zhejiang Pharmaceutical plans to spin off its subsidiary, Zhejiang Xima Biotechnology Co., Ltd., for a listing on the Hong Kong Stock Exchange [1] - The spin-off aims to enhance the development of the biopharmaceutical sector, broaden financing channels, and improve overall profitability and core competitiveness of Zhejiang Pharmaceutical [1] - The spin-off will not result in Zhejiang Pharmaceutical losing control over Xima Biotechnology and will not adversely affect other business segments or the company's overall profitability [1] Group 2 - Xima Biotechnology focuses on the research and production of biopharmaceuticals and is the R&D mainstay of Zhejiang Pharmaceutical's biopharmaceutical sector [2] - In early November, Xima Biotechnology completed a strategic acquisition of all preclinical pipelines and corresponding platform technology patents from Shanghai New Concept Biotechnology Co., Ltd., enhancing its R&D capabilities [2] - The acquisition brought in Dr. Han Nian, a scientist with nearly 30 years of experience in the biopharmaceutical industry, to serve as Chief Scientific Officer, strengthening Xima Biotechnology's expertise in drug development [2]

Group 1 - The Ministry of Commerce of China and the European Commission discussed semiconductor supply chain issues, emphasizing the need for constructive communication between ASML Netherlands and ASML China to stabilize the global semiconductor supply chain [2] - Vanke faced a significant decline in both stock and bond markets, with some bonds dropping over 35% and the stock price nearing historical lows, prompting a meeting regarding bond extension [2] - The Chinese government instructed domestic airlines to reduce flights to Japan before March 2026, reflecting ongoing diplomatic tensions [3] Group 2 - Six departments in China released a plan to enhance the adaptability of consumer goods supply and demand, aiming for a significant optimization of the supply structure by 2027 [3] - The National Development and Reform Commission announced a new management method for credit repair, effective from April 2026, categorizing dishonest information into three levels [3] - The A-share market saw fluctuations, with the Shanghai Composite Index closing down 0.15%, while the Shenzhen Component Index and the ChiNext Index recorded gains [4] Group 3 - Li Auto reported a 36.2% year-on-year decline in Q3 revenue, with an adjusted net loss of 360 million yuan, and projected a further decline in Q4 revenue [5] - The insurance sector welcomed new funds into long-term investment trials, with a new private equity fund entering operation [4] - The Chinese Nonferrous Metals Industry Association opposed the zero or negative processing fees in the copper smelting industry, calling for better management of copper smelting capacity [8] Group 4 - The medical device market in China is expected to reach 1.22 trillion yuan by 2025, with a significant increase in the number of production enterprises [9] - The financial support plan in Guangdong aims to facilitate industry chain integration and improve the quality of listed companies [8] - The Hong Kong stock market saw a net sell-off of 39.52 billion HKD by southbound funds, with notable movements in major tech stocks [4]

Focus 1: Jianlong Micro-Nano (688357) - The company has terminated the planning of a major asset restructuring, which was intended to acquire at least 51% of Shanghai Hanxing Energy Technology Co., Ltd. through cash payment for equity [1] Focus 2: Industrial Fulian - The company has adjusted the maximum repurchase price for its shares from 19.36 yuan per share to 75.00 yuan per share, reflecting confidence in its future development and market conditions [2] Focus 3: *ST Dongtong - The company received a prior notice from the Shenzhen Stock Exchange regarding the proposed termination of its stock listing [3] Focus 4: Fundraising & Restructuring - Aolaide plans to raise up to 299.71 million yuan through a simplified procedure for issuing shares to specific targets, with proceeds allocated for OLED display core material production and working capital [4] - Maigemi has received approval from the Shenzhen Stock Exchange for its application to issue shares to specific targets, meeting all necessary conditions [4] - Su Yan Jingshen has also received approval for its share issuance application, pending final registration with the China Securities Regulatory Commission [4] Focus 5: Important Matters - Baiao Chemical's major shareholders are transferring a total of 10% of the company's shares to Liu Hongjun, resulting in him holding 10% of the total share capital post-transfer [5][6] - Zhejiang Pharmaceutical is planning to spin off its subsidiary for a listing on the Hong Kong Stock Exchange, which will not affect its control over the subsidiary [6] - Huafeng Aluminum is acquiring 100% of Shanghai Huafeng Puen Polyurethane Co., Ltd. for 100.06 million yuan, which will enhance its operational efficiency and market competitiveness [7] Focus 6: New Investments - Fuda Co. is establishing a wholly-owned subsidiary with an investment of 30 million yuan to enhance its forging business and related manufacturing capabilities [8] - Jianghai Co. is forming a joint venture to establish an innovation research institute with a registered capital of 50 million yuan, focusing on strategic technology research [9][10] Focus 7: Capital Market Activities - Zhongshan Bank has issued 60 billion yuan of subordinated debt with a fixed interest rate of 2.16% for a term of 10 years [17] - China Iron and Steel Group plans to increase its stake in China Iron and Steel Co. by investing between 65 million and 130 million yuan over the next six months [18]

Core Viewpoint - Zhejiang Medicine announced the approval of a restricted stock incentive plan for 2025, granting 10.284 million shares to 875 recipients at a price of 7.30 yuan per share [1] Group 1 - The company held its 10th ninth board meeting on November 26, 2025, to review the incentive plan [1] - The conditions for granting restricted stock to the incentive plan participants have been met as of the grant date [1] - The stock grant is part of the company's strategy to motivate and retain key personnel [1]

证券日报网讯 11月26日晚间，浙江医药发布公告称，公司于2025年11月26日召开第十届九次董事会会 议，审议通过了《关于筹划控股子公司分拆上市的议案》，公司拟筹划分拆控股子公司浙江新码生物医 药有限公司于香港联合交易所有限公司上市。 （编辑 任世碧） ...